Chaired by Jorge Capapey, Managing Director of Alnylam in Spain, the new board will have three vice-chairs: Mª José Sánchez, Managing Director of CSL Behring in Spain and Portugal; Leticia Beleta, Managing Director of Alexion in Spain; and David Moreno, Managing Director of PTC Therapeutics in Spain.

The association wants to continue to promote the value of orphan drugs and advanced therapies, promoting rapid and equal access to patients with these rare diseases.
The new Board of Directors is composed of professionals with extensive experience in the area of rare diseases and who represent highly innovative companies focused on the development of treatments for unmet medical needs of these diseases, aimed at improving the quality of life of patients.

The president of the association, Jorge Capapey, has highlighted the complex situation in which the Spanish healthcare system finds itself after the COVID-19 crisis, stressing that one of AELMHU's main challenges will be to work to ensure that the care of patients with these pathologies is not negatively impacted.